Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2023 – Breast Cancer
ASCO 2023 - Breast Cancer
Tucatinib Plus Trastuzumab Plus Capecitabine Is Efficacious After Trastuzumab Deruxtecan Exposure in HER2-Positive MBC
ASCO 2023 - Breast Cancer
Results of a large multicenter retrospective study confirmed that tucatinib in combination with trastuzumab and capecitabine was efficacious in patients with HER2-positive metastatic breast cancer with previous exposure to trastuzumab deruxtecan.
Read More ›
HER2 REAL: Real-World Treatment Patterns in HER2-Positive Unresectable LA/MBC
ASCO 2023 - Breast Cancer
Interim results from the Asia cohort of the HER2 REAL study found heterogeneous treatment patterns among patients with HER2-positive unresectable locally advanced or metastatic breast cancer progressing on HER2-directed therapies.
Read More ›
PERMEATE: Updated Results of Pyrotinib Plus Capecitabine in Patients With HER2-Positive MBC and Brain Metastases
ASCO 2023 - Breast Cancer
Updated results of the phase 2 PERMEATE trial confirmed that pyrotinib plus capecitabine provided long-term survival benefit in patients with HER2-positive metastatic breast cancer and brain metastases.
Read More ›
HER2CLIMB-05: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2-Positive LA/MBC
ASCO 2023 - Breast Cancer
The phase 3 HER2CLIMB-05 trial is evaluating tucatinib plus trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive locally advanced or metastatic breast cancer.
Read More ›
PRECIOUS: Pertuzumab Re-treatment Improved OS in HER2-Positive LA/MBC in a Phase 3 Trial, but Did Treatment Imbalances Impact the Outcomes?
ASCO 2023 - Breast Cancer
Updated results of the phase 3 randomized PRECIOUS trial demonstrated that dual HER2 blockade with pertuzumab re-treatment in combination with trastuzumab plus chemotherapy led to significant overall survival improvement compared with trastuzumab plus chemotherapy in patients previously treated with pertuzumab-containing regimens for HER2-positive locally advanced/metastatic breast cancer, but potential imbalances in chemotherapy during and after the study treatment period may have impacted the results.
Read More ›
Page 2 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us